

Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn

- Vaxdyn's project to develop a new multi-antigen vaccine against serious bacterial infections, including pneumonia, is in early stages, and is funded by CARB-X, global biopharmaceutical accelerator to combat antibiotic resistance
- Reig Jofre along with the National Center of Microbiology of the Spanish Institute of Health Carlos III are part of the consortium led by the biotech Vaxdyn
- An estimated 700,000 people die each year from drug-resistant bacterial infections, and the death toll is expected to rise unless new preventatives and treatments are found

Barcelona (Spain), July 16, 2020, Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, participates in the based in Seville, Spain biotech Vaxdyn consortium to develop a new multi-antigen vaccine against serious bacterial infections caused by *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*, which could prevent antibiotic-resistant pneumonia in patients with elevated risk, such as those affected by chronic lung diseases, diabetes or undergoing cancer treatment.

With an extensive experience of more than 10 years in pharmaceutical development, industrial scaling of innovative injectable biological products that require specialization to stabilize by lyophilization, Reig Jofre will contribute to this consortium its expertise in the analytical strategy, quality control and definition of the process for the production of clinical batches and guarantee the subsequent industrial scale-up of the vaccine of Vaxdyn.

An estimated 700,000 people die each year from drug-resistant bacterial infections, and the death toll is expected to rise unless new preventatives and treatments are found. Pneumonia can be caused by many types of bacteria, including drug-resistant bacteria and is one of the world's leading cause of death which disproportionately affects the children, the elderly, and the immunocompromised.



The Vaxdyn multi-antigen vaccine project against serious bacterial infections has been funded by the global biopharmaceutical accelerator to combat antibiotic resistance, CARB-X, with €803 thousand, plus an additional €5,7 million if certain project milestones are met. CARB-X, led by Boston University, is funded by the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), the UK Government's Global AMR Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation devoted to help people around the world to lead healthy and productive lives.

Vaxdyn's CEO Juanjo Infante states: "Reig Jofre has extensive experience in the development and production of injectable and lyophilized pharmaceutical products. Their knowledge to advance towards the clinical phases is instrumental and their versatile and adapted industrial capacities for the manufacture of biotechnological vaccines, make Reig Jofre the strategic partner for pharmaceutical and industrial development"

The director of parenteral developments of Reig Jofre, Gemma Lahuerta, highlights: "it is a challenge and a pride to contribute our knowledge and experience in the development and production of a vaccine to combat the three pathogens of highest priority among those resistant to antibiotics for the World Health Organization and that affect risk groups as in the case of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)."

Reig Jofre closed 2019 with a turnover of 200 million euros. During the last 5 years, the company has allocated 48 million euros to research programs, representing approximately 5% of annual sales. For the marketing of its developments, Reig Jofre has its own sales network in 7 countries in Europe and Southeast Asia and trade relations with more than 130 partners (distributors and licensees) in 72 countries worldwide.

Receive updated news about Reig Jofre by registering with the company's **subscription centre** via our corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a family-controlled pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements from its four plants in Toledo (2), Barcelona and Malmö (Sweden). Reig Jofre structures its product development activity in three business areas: (1) *Pharmaceutical technologies* specialized in sterile and lyophilized injectables, and antibiotics derived from



penicillin; (2) *Specialty Pharmacare* in dermatology; Joint Pain, and Women's Health (developed and produced internally), and (3) *Consumer Healthcare*, with products aimed at the consumer under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and other OTCs. Reig Jofre has more than 1000 employees, direct sales in 7 countries and more than 130 business partners in 72 countries around the world. The company closed 2019 with a turnover of 200 million Euros. Reig Jofre is listed the ticker RJF. Share capital: 76,062,457 shares

About Vaxdyn

Vaxdyn is dedicated to improving quality of life in populations affected by infections globally. Headquartered in Seville, Spain, and born from decades of research on infectious diseases and antibiotic resistance, Vaxdyn's vision is to create specific immunity in high-risk populations against the most antibiotic resistant bacterial pathogens. Vaxdyn works with an international network of collaborators in the development of multi-valent vaccines for preventing infections in individuals affected by chronic diseases of the lungs, liver, kidney, immunocompromised by several co-morbidities such as diabetes or cancer, and populations associated with nursing homes and hospital settings. Vaxdyn is strongly committed to implementing its technology for combating infections in the most vulnerable regions of the world. <http://www.vaxdyn.com/> Twitter: @vaxdyn

Further information

Inma Santa-Pau - Director of Communication and Investor Relations
Tel. (+34) 935 450 078 - inma.santapau@reigjofre.com
www.reigjofre.com